Mutations in TET2 and TP53: A Double Whammy in Blood Cancers
Thu Mar 20 2025
Scientists have found that certain mutations often go hand in hand in blood cancers. These mutations can make the disease worse and harder to treat. One such pair is mutations in the genes TET2 and TP53. These mutations can work together to make blood cancers more aggressive. They can also create an environment that helps the cancer grow and evades the body's defenses.
In lab experiments, mice with both TET2 and TP53 mutations developed a type of blood cancer called acute myeloid leukemia (AML). This type of AML was more likely to come back after treatment. The cancer cells in these mice had a higher ability to renew themselves. This means they could keep making more cancer cells. This is a big problem because it makes the cancer harder to get rid of.
The cancer cells in these mice also had changes in their immune signals. These changes helped the cancer cells hide from the body's immune system. The immune system is supposed to fight off invaders like cancer cells. But in these mice, the cancer cells were able to trick the immune system into leaving them alone. This is a sneaky way for the cancer to survive and grow.
One way the cancer cells did this was by increasing the number of certain immune cells. These cells are called myeloid-derived suppressor cells. They can stop other immune cells, like T cells, from working properly. This makes it even harder for the body to fight the cancer. The cancer cells also had more of a certain protein on their surface. This protein can stop another type of immune cell, called natural killer cells, from attacking the cancer cells.
But there's some good news. Scientists found that blocking this protein with special antibodies could help. These antibodies made the natural killer cells better at killing the cancer cells. They also helped the mice live longer. This is a promising finding. It shows that there might be new ways to treat this type of blood cancer.
The immune system is a complex network of cells and signals. It's supposed to protect the body from invaders. But in some cases, like this type of blood cancer, the immune system can be tricked. The cancer cells can use the immune system's own signals against it. This is a clever way for the cancer to survive and grow. But it also gives scientists new targets for treatments. By understanding how the cancer tricks the immune system, they can find ways to outsmart it.
The findings also highlight the importance of looking at more than just one mutation. In many cases, blood cancers have multiple mutations. These mutations can work together to make the cancer more aggressive. By understanding how these mutations interact, scientists can develop better treatments. They can also find new ways to predict how the cancer will behave. This is important for choosing the best treatment for each patient.
https://localnews.ai/article/mutations-in-tet2-and-tp53-a-double-whammy-in-blood-cancers-b0eaacf8
continue reading...
questions
How do TP53 mutations specifically contribute to the adverse outcomes in patients with myeloid malignancies?
What are the potential mechanisms by which TET2 deficiency enhances self-renewal in combination with TP53 mutations?
What other genetic alterations might cooperate with TP53 mutations to drive leukemogenesis, and how can they be identified?
actions
flag content